Detalhe da pesquisa
1.
Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA.
Lancet
; 402(10419): 2307-2316, 2023 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37979595
2.
Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 402(10404): 775-785, 2023 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37516125
3.
Atogepant for the Preventive Treatment of Migraine.
N Engl J Med
; 385(8): 695-706, 2021 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407343
4.
Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.
Cephalalgia
; 43(1): 3331024221128250, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36620892
5.
Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis.
Headache
; 63(8): 1135-1144, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37655536
6.
Evaluating therapeutic benefits of ubrogepant via latent class models: A post hoc exploratory analysis of the ACHIEVE I and ACHIEVE II trials.
Headache
; 63(10): 1412-1422, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37873925
7.
Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial.
Headache
; 63(1): 79-88, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36651532
8.
Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
Headache
; 63(3): 322-332, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36602199
9.
Ubrogepant for the Treatment of Migraine.
N Engl J Med
; 381(23): 2230-2241, 2019 12 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31800988
10.
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
Cephalalgia
; 42(1): 3-11, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34521260
11.
Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications.
Cephalalgia
; 41(5): 546-560, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33241721
12.
Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
Headache
; 61(3): 422-429, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33749826
13.
Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II.
Headache
; 60(4): 686-700, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32073660
14.
Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.
Headache
; 60(1): 141-152, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31913519
15.
Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults.
Cephalalgia
; 39(14): 1753-1761, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31537107
16.
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
JAMA
; 322(19): 1887-1898, 2019 11 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31742631
17.
Atogepant: Mechanism of action, clinical and translational science.
Clin Transl Sci
; 17(1): e13707, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38266063
18.
Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial.
Lancet Neurol
; 23(4): 382-392, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38364831
19.
Effects of CYP3A4 inhibition/induction and OATP inhibition on the pharmacokinetics of atogepant in healthy adults.
Pain Manag
; 2023 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37650778
20.
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain.
Neurology
; 99(17): e1905-e1915, 2022 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35977836